Use of Plasma Rich in Growth Factors and ReGeneraTing Agent Matrix for the Treatment of Corneal Diseases
| Autor: | Jesus Merayo-Lloves, Edmar Uribe-Badillo, Carlos Fernández-Vega González, Eduardo Anitua, Borja de la Sen-Corcuera, Francisco Muruzabal, Begoña Baamonde, Luis M. Quirós, Ronald M Sanchez-Avila |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Intraocular pressure medicine.medical_specialty PRP genetic structures Visual analogue scale QH301-705.5 Cognitive Neuroscience corneal ulcers Article 03 medical and health sciences 0302 clinical medicine Herpes virus Ophthalmology Medicine Ocular Surface Disease Index Biology (General) PRGF RGTA matrix ocular surface diseases business.industry Corneal Diseases Mean age Cell Biology Sensory Systems eye diseases 030104 developmental biology 030221 ophthalmology & optometry Neurotrophic corneal ulcer sense organs business Optometry Corneal disease |
| Zdroj: | Vision, Vol 5, Iss 34, p 34 (2021) Vision Volume 5 Issue 3 Scopus RUO. Repositorio Institucional de la Universidad de Oviedo instname |
| ISSN: | 2411-5150 |
| Popis: | This study aimed to investigate the use of Plasma Rich in Growth Factors (PRGF) associated with tissue ReGeneraTing Agent (RGTA) drops for the treatment of noninfectious corneal ulcers. RGTA treatment was applied (one drop every two days) however, if ulcer closure was not achieved, PRGF eye drops treatment was added (four times/day). The time taken to reach the ulcer closure, the Best Corrected Visual Acuity (BCVA), intraocular pressure (IOP), Visual Analog Scale (VAS, in terms of frequency and severity of symptoms), and Ocular Surface Disease Index (OSDI) were evaluated. Seventy-four patients (79 eyes) were included, and the mean age was 56.8 ± 17.3 years. The neurotrophic corneal ulcer was the most frequent disorder (n = 27, 34.2%), mainly for herpes virus (n = 15, 19.0%). The time of PRGF eye drops treatment associated with the RGTA matrix was 4.2 ± 2.2 (1.5–9.0) months, and the follow-up period was 44.9 ± 31.5 months. The ulcer closure was achieved in 76 eyes (96.2%). BCVA, VAS and OSDI improved from the baseline (p < 0.001), and IOP remained unchanged (p = 0.665). RGTA and PRGF in noninfectious ulcers were effective and could be a therapeutic alternative for this type of corneal disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|